Vivoryon Therapeutics NV Announces Last-Minute Oral Presentation at American Society of Nephrology Kidney Week 2024 | 11.10.24

Halle (Saale) / Munich, Germany, October 11, 2024 – Vivoryon Therapeutics NV (Euronext Amsterdam: VVY; NL00150002Q7) (Vivoryon), a clinical-stage company focused on the discovery and development of small molecule drugs to modulate the activity and stability of pathologically altered proteins, today announced that the company’s summary “Varoglutamstat increases glomerular filtration in elderly patients without signs of proteinuria and Potentially Offers a New Approach to Treating Diabetic Kidney Disease (DKD)” was selected for a last-minute oral presentation at the American Society of Nephrology (ASN) Kidney Week 2024 in San Diego, California, held October 23-27.

“We are really excited that our abstract was selected for a last-minute oral presentation at ASN Kidney Week 2024,” said Frank Weber, MD, CEO of Vivoryon. and doctors specializing in the renal field.”

ASN Kidney Week 2024 presentation details:

###

Varoglutamstat in Kidney Disease
Varoglutamstat (PQ912) is a proprietary, potent and selective inhibitor of human glutaminyl cyclases QPCT and QPCTL with therapeutic potential in indications including inflammatory and fibrotic diseases, neurodegenerative diseases, cancer and others. Initially advancing in development with the goal of treating Alzheimer’s disease (AD), varoglutamstat has been investigated in several different clinical studies, all of which have consistently demonstrated a favorable safety and tolerability profile in both healthy volunteers and AD patients. . Based on the known anti-inflammatory activity of varoglutamstat, the protocol for the phase 2 VIVIAD study in AD, which was completed in the first half of 2024, included investigation of renal function and measurement of biomarkers of inflammation and renal fibrosis to explore the role of QPCT/L inhibition in renal function. Although VIVIAD patients were selected for their AD status rather than their level of kidney function, many of them have reduced kidney function due to age and/or comorbidities.

About Vivoryon Therapeutics NV
Vivoryon is a clinical-stage biotechnology company focused on developing innovative medicines based on small molecules. Driven by its passion for groundbreaking science and innovation, the Company strives to change the lives of patients in need suffering from serious illnesses. The Company leverages its deep expertise in understanding post-translational modifications to develop medicines that modulate the activity and stability of proteins that are altered in disease settings. The company has established a pipeline of orally available small molecule inhibitors for a variety of indications, including Alzheimer’s disease, inflammatory and fibrotic disorders, including kidney, and cancer. www.vivoryon.com.

Vivoryon Forward-Looking Statements
This press release includes forward-looking statements, including, without limitation, those relating to Vivoryon Therapeutics NV’s (the “Company”) business strategy, management plans and objectives for future operations, estimates and projections regarding the market for Vivoryon Therapeutics NV’s products. Enterprise. and forecasts and statements about when the Company’s products may be available Words such as “anticipate”, “believe”, “estimate”, “expect”, “predict”, “intend”, “may”, “plan”, “. project ”, “anticipate”, “should” and “will” and similar expressions relating to the Company are intended to identify such forward-looking statements. These forward-looking statements are not guarantees of future performance; the economy and other future conditions. Forward-looking statements involve a number of known and unknown risks and uncertainties and other factors may adversely affect the results and financial effects of the plans and events described herein. The Company’s cash flow, financial condition, liquidity, prospects, future transactions, strategies or events may differ materially from those expressed or implied by such forward-looking statements and expectations. As a result, no undue reliance should be placed on such forward-looking statements. This press release does not contain risk factors. Certain risk factors that may affect the Company’s future financial results are discussed in the Company’s published annual financial statements. This press release, including any forward-looking statements, speaks only as of the date of this press release. The Company undertakes no obligation to update any forward-looking information or statements contained herein, except for any information required to be disclosed by law.

For more information, contact:

Contact with investors

Vivoryon Therapeutics NV
Dr. Manuela Bader, Director of IR and Communication
E-mail: [email protected]

Media contact

Trophic Communications
Stephanie May
Tel: +49 171 1855682
E-mail: [email protected]

• 241011_VVY_ASN Kidney Week